The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•1 May 2026•

1 min read

Thermo Fisher Posts 6% Q1 Growth and Completes $9.1B Clario Acquisition

Key Facts

1Thermo Fisher Q1 revenue grew 6% year-over-year to reach $11.01 billion.

2The company completed the acquisition of Clario Holdings for $9.1 billion to expand clinical research offerings.

3The company plans to sell its microbiology business for approximately $1.08 billion to optimize its portfolio.

Thermo Fisher Scientific reported robust financial results for the first quarter, with revenue increasing 6% year-over-year to $11.01 billion. Alongside the earnings release, the company finalized its $9.1 billion acquisition of Clario Holdings, a strategic move designed to significantly expand its clinical research service offerings. Furthermore, the company announced plans to divest its microbiology business for approximately $1.08 billion as part of a broader portfolio optimization strategy. These developments, coupled with $3.0 billion in share buybacks, underscore the firm's focus on operational efficiency and capital return. Analysts view the combination of organic growth and large-scale M&A activity as a strong signal of the company's long-term competitive positioning in the healthcare sector.